Medidata Solutions, Inc. (NASDAQ:MDSO) – Research analysts at KeyCorp cut their FY2017 earnings estimates for Medidata Solutions in a note issued to investors on Sunday. KeyCorp analyst D. Hooker now forecasts that the company will post earnings of $0.74 per share for the year, down from their prior estimate of $0.75. KeyCorp currently has a “Buy” rating and a $86.00 price objective on the stock. KeyCorp also issued estimates for Medidata Solutions’ FY2018 earnings at $1.00 EPS.

Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings results on Tuesday, July 18th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.03. Medidata Solutions had a net margin of 7.07% and a return on equity of 11.14%. The firm had revenue of $137.41 million during the quarter, compared to the consensus estimate of $134.28 million. During the same period last year, the firm posted $0.24 EPS. The firm’s quarterly revenue was up 19.9% on a year-over-year basis.

WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/20/fy2017-eps-estimates-for-medidata-solutions-inc-cut-by-analyst-mdso.html.

A number of other equities research analysts also recently issued reports on MDSO. Zacks Investment Research upgraded shares of Medidata Solutions from a “sell” rating to a “hold” rating in a research note on Wednesday. Royal Bank Of Canada assumed coverage on shares of Medidata Solutions in a research note on Tuesday. They set a “sector perform” rating and a $82.00 price objective on the stock. Jefferies Group LLC reiterated a “hold” rating and set a $78.00 price objective on shares of Medidata Solutions in a research note on Tuesday, August 22nd. Morgan Stanley set a $74.00 price objective on shares of Medidata Solutions and gave the stock a “buy” rating in a research note on Wednesday, June 14th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $90.00 price objective (up from $75.00) on shares of Medidata Solutions in a research note on Friday, July 21st. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $83.83.

Medidata Solutions (NASDAQ MDSO) opened at 75.57 on Wednesday. The company’s 50-day moving average is $74.60 and its 200 day moving average is $70.33. The company has a market capitalization of $4.28 billion, a P/E ratio of 122.08 and a beta of 1.81. Medidata Solutions has a one year low of $46.10 and a one year high of $85.92.

In other news, COO Michael L. Capone sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $74.53, for a total value of $372,650.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 5.80% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of MDSO. BNP Paribas Arbitrage SA boosted its stake in shares of Medidata Solutions by 9.8% in the 1st quarter. BNP Paribas Arbitrage SA now owns 11,171 shares of the company’s stock valued at $644,000 after purchasing an additional 997 shares in the last quarter. Comerica Bank boosted its stake in shares of Medidata Solutions by 5.0% in the 1st quarter. Comerica Bank now owns 61,305 shares of the company’s stock valued at $3,997,000 after purchasing an additional 2,936 shares in the last quarter. LS Investment Advisors LLC boosted its stake in shares of Medidata Solutions by 44.6% in the 1st quarter. LS Investment Advisors LLC now owns 3,310 shares of the company’s stock valued at $191,000 after purchasing an additional 1,021 shares in the last quarter. Swiss National Bank boosted its stake in shares of Medidata Solutions by 0.8% in the 1st quarter. Swiss National Bank now owns 95,300 shares of the company’s stock valued at $5,498,000 after purchasing an additional 800 shares in the last quarter. Finally, World Asset Management Inc acquired a new stake in shares of Medidata Solutions in the 1st quarter valued at approximately $201,000. Institutional investors own 97.52% of the company’s stock.

Medidata Solutions Company Profile

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.